Skip to main content
. 2022 Dec 19;10(12):3294. doi: 10.3390/biomedicines10123294

Figure 2.

Figure 2

(A) Properly functioning nephron. (B) The mechanism of nephron impairment in the course of long-term, inappropriately treated DM. (C) Effect of SGLT2 inhibitor empagliflozin on improving intraglomerular pressure and GFR in DM [42]. SGLT1, SGLT2—sodium-glucose transport proteins, JGA—juxtaglomerular apparatus.